Latest

Why Is It Such a Challenge to Treat PAH?

Despite recent advances, there continue to be significant issues that compromise the effective management of pulmonary arterial hypertension, writes Victoria Allan.

Pharma 50 2015: Slide Show

A quick countdown of this year's Top 50 movers and shakers.

New & Noteworthy

Taking Flight: Pharm Exec's Top 50 Pharma Companies 2015

Our annual Pharma 50 listing is clear proof that once-small and midsize biopharma companies are moving up to join the top ranks of big Pharma.

Too Many Breakthroughs?

FDA wants pharma to be more selective in seeking special status for promising therapies. Jill Wechsler reports.

Big Data Innovation and Risk: How to Strike the Balance

As the industry continues to face declining R&D productivity, one efficient way of making the failure rate lower is to use data, writes Adam Towvim.

Beyond the Buzzword: Finding Your Patient Centricity

SPONSORED CONTENT. The term “patient centric” has become something of a catch-all term. Cheryl Lubbert looks at the broad range of its application.

Towards Real-World Patient Centricity

Patient centricity requires clinical trials to be based on life outside the lab, writes Mikkel Brok-Kristensen.

Outlook: Market Access in Australia

Despite recent challenges, the Australian market still offers a number of opportunities for pharma manufacturers.

Optimizing Clinical Trials Using Electronic Measurement and Analysis of Drug Adherence

Drug development has never before been so difficult, time consuming and expensive. Accuracy in clinical trials, therefore, is a priority

From the Editor

Health Innovation: Creating Next Gen Leaders

Institutionalizing the teachable moment with GENiE, a new network focused on advancing the idea that for healthcare to change, the education of its leaders must change first.

From Care to Cure

This year's Pharm Exec Brand of the Year is a huge game-changers, but the big-picture impact will come down to pricing, distribution, and the broader goal of making sure that those patients who need the cure, get the cure, writes William Looney.

Europe

Joint Procurement Moves Up the EU Agenda

With Ireland’s signing of a vaccine procurement agreement this month, the EU’s move toward joint action on medicine acquisition is gathering pace, writes Reflector.

NICE Proposes Office of Market Access

NICE's proposed Innovation Office emerges with a new name. Leela Barham reports.

Global

Globalization of Biomanufacturing Outsourcing Continues

While the United States and Europe still dominate, CMOs and CROs based in emerging markets continue to capture market share.

Regulatory Dark Horse? EU Directive on Cross-Border Patients’ Rights

Reflector looks at the revitalized European Union directive on patients’ rights in cross-border healthcare.

PEspeaks

“Rx” for the Latest SCOTUS Decision on Obamacare

For the second time in three years, the Supreme Court of the United States (SCOTUS) has weighed in on key aspects of the 2010 Obamacare law. Tom Norton reports.

Four Launch Mistakes and How to Avoid Them

In the white heat of a major brand launch, we can become consumed by the day to day challenges and make mistakes. But some of the worst mistakes can be avoided with a little foresight, writes Ken Begasse.

Pharma's Trillion-Dollar Sales Trophy: Will Payers Pony Up?

William Looney looks at the key predictions from EvaluatePharma's World Preview 2015, launched at last week's BIO International Convention.

Can Facebook Hurt Your Clinical Trial?

Conversely, social media discussions about study requirements and procedures may discourage participation and undermine study integrity, according to experts at last week’s Drug Information Association (DIA) annual meeting in Washington, D.C.

Regulatory

Too Many Breakthroughs?

FDA wants pharma to be more selective in seeking special status for promising therapies. Jill Wechsler reports.

Antibiotics, “Cures” Legislation Top Priorities for FDA Acting Commissioner

Jill Wechsler cast her eye over FDA acting commissioner Stephen Ostroff's international plans.

Drug Contamination Problems Hit NIH

Drug quality issues have forced the National Institutes of Health to shutter its in-house facility for producing clinical supplies for certain clinical trials. Jill Wechsler reports.

Sales & Marketing

Beyond the Buzzword: Finding Your Patient Centricity

SPONSORED CONTENT. The term “patient centric” has become something of a catch-all term. Cheryl Lubbert looks at the broad range of its application.

When Care Models Collide

What you should know about integrated delivery networks, by Kim White and Christen Buseman.

Why the Emotional Sell is More Critical Than Ever

Whether a brand is preparing to launch a new product, or taking a reinvigorated one back to market, it is widely accepted that those who form the emotional connection with customers are most likely to succeed.

R&D

Optimizing Clinical Trials Using Electronic Measurement and Analysis of Drug Adherence

Drug development has never before been so difficult, time consuming and expensive. Accuracy in clinical trials, therefore, is a priority

Refuting R&D Tax Credit Myths

Why executives should make the US R&D tax credit part of their planning discussions.